Claims
- 1. An isolated polypeptide consisting of a full length NS2/3 protease or a truncation thereof having as its N-terminal residue any one amino acid from amino acid 810 to amino acid 906.
- 2. An isolated polypeptide consisting of a truncation of an HCV NS2/3 protease, wherein said truncated NS2/3 protease has the minimal amino acid sequence from residues 904 to 1206 of the HCV 1b-40 full-length NS2/3 protease.
- 3. An isolated polypeptide consisting of a truncated NS2/3 protease as defined according to SEQ ID. NO: 4 or 10.
- 4. An isolated polypeptide consisting of an amino acid sequence that has 90% identity over its length compared to the polypeptide according to claim 3.
- 5. An isolated polypeptide consisting of a truncated NS2/3 protease selected from the group consisting of: a sequence as defined according to SEQ ID. NOs: 11, 12, 13, 14 and 15.
- 6. A peptide having the sequence SFEGQGWRLL (SEQ ID NO:21).
- 7. A peptide according to claim 6, wherein said peptide is a NS2/3 protease inhibitor.
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser. No.10/017,736, filed Dec. 14, 2001, which claims, as does the present application priority to U.S. Provisional Application Serial No. 60/256,031, filed on Dec. 15, 2000, the disclosures of all of which are incorporated by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60256031 |
Dec 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10017736 |
Dec 2001 |
US |
Child |
10650585 |
Aug 2003 |
US |